American Journal of Cardiology最新文献

{"title":"“It ain’t over till it’s over”—Yogi Berra","authors":"Roger M. Mills MD","doi":"10.1016/j.amjcard.2026.03.012","DOIUrl":"10.1016/j.amjcard.2026.03.012","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"268 ","pages":"Pages 178-179"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombus and Healing in Femoropopliteal Arterial Disease: Insights Into the Mechanisms of Symptomatic Peripheral Arterial Disease Progression","authors":"Nicolas W. Shammas MD, MS, FACC, FSCAI","doi":"10.1016/j.amjcard.2026.03.009","DOIUrl":"10.1016/j.amjcard.2026.03.009","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"268 ","pages":"Pages 176-177"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Apixaban Versus Warfarin in Atrial Fibrillation Patients with Malignancy: A Propensity-Matched Analysis","authors":"Siddharth P. Agrawal MD ,&nbsp;Ritu Tated MBBS, MPH ,&nbsp;Hritvik Jain MBBS ,&nbsp;Kriti Soni MD ,&nbsp;Dhruvi K. Joshi MBBS ,&nbsp;Pragyat Futela MD ,&nbsp;Maharshi Raval MD ,&nbsp;Vikas Aggarwal MD ,&nbsp;Abhishek Deshmukh MD ,&nbsp;Saraschandra Vallabhajosyula MD, MSc","doi":"10.1016/j.amjcard.2026.01.006","DOIUrl":"10.1016/j.amjcard.2026.01.006","url":null,"abstract":"<div><div>Patients with atrial fibrillation and malignancy have increased risks of thromboembolism and bleeding. Evidence comparing apixaban and warfarin in this group remains limited. We aimed to compare effectiveness and safety of apixaban versus warfarin in patients with atrial fibrillation and active malignancy using real-world data from a large multinational cohort. This retrospective cohort study used the TriNetX Global Collaborative Network, de-identified records from 146 healthcare organizations between December 1, 2012, and May 1, 2025. Atrial fibrillation patients with malignancy receiving apixaban or warfarin were matched 1:1 using propensity scores across 74 clinical variables. Outcomes were assessed at 3 months, 6 months, 1 year, and 5 years. Primary endpoints included all-cause mortality, stroke, pulmonary embolism, deep vein thrombosis, gastrointestinal bleeding and intracranial hemorrhage. In this 12.5-year period, 41,764 matched pairs of patients were analyzed. Compared to the warfarin cohort, the apixaban cohort demonstrated lower all-cause mortality at 3 months (OR: 1.05, 95% CI: 1.00–1.10), 6 months (OR: 1.05, 95% CI: 1.01–1.09), 1 year (OR: 1.06, 95% CI: 1.03–1.10), and 5 years (OR: 1.17, 95% CI: 1.13–1.20; all p &lt;0.05). Stroke rates were comparable between groups, while pulmonary embolism, deep vein thrombosis, gastrointestinal bleeding and intracranial hemorrhage were noted less frequent with apixaban. Kaplan–Meier analyses showed early and sustained differences in survival and bleeding outcomes. In conclusion, in atrial fibrillation patients with cancer, apixaban was associated with lower mortality and major bleeding without increasing stroke risk compared to warfarin.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"264 ","pages":"Pages 14-20"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146002850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Suitability of Patients for Transcatheter Tricuspid Valve Replacement","authors":"Tyler Andrews DO ,&nbsp;Ritik Patel BS ,&nbsp;Muhtasim Jaigirdar MD ,&nbsp;PedroEngel Gonzalez MD ,&nbsp;Dimitrios Apostolou MD ,&nbsp;James Lee MD ,&nbsp;John Dawdy MD ,&nbsp;Bryan Zweig MD ,&nbsp;Raed Alnajjar MD ,&nbsp;Tiberio M. Frisoli MD ,&nbsp;Pedro Villablanca MD ,&nbsp;Brian P. O’Neill MD","doi":"10.1016/j.amjcard.2026.01.002","DOIUrl":"10.1016/j.amjcard.2026.01.002","url":null,"abstract":"<div><div>Transcatheter tricuspid valve replacement (TTVR) has shown therapeutic promise for patients with severe tricuspid regurgitation (TR). However, some patients may not be eligible due to anatomic limitations. We sought to describe the outcomes of patients who were referred for transcatheter tricuspid valve intervention (TTVI) and were ineligible for TTVR. This was a single-center, retrospective study of 251 patients referred for TTVI from February 2024 to August 2025. All patients were considered by a multidisciplinary heart team and assessed for feasibility of commercial tricuspid valve repair or replacement, with a strategy to proceed with replacement if anatomically feasible. Data on demographics, clinical characteristics, and outcomes were collected from medical records. Of 251 patients evaluated, 43 (17.1%) were unsuitable for TTVR. Compared with suitable patients, unsuitable patients were more frequently male (67.4% vs 33.2%, p &lt;0.01) and more likely to have implanted electronic device (53.5% vs 32.2%, p = 0.01) or prior tricuspid interventions (7.9% vs 1.6%, p = 0.03). The leading reason for unsuitability was large annular dimensions (60.5%), followed by leaflet tethering (14.0%) and small annular size (11.6%). Of the unsuitable cohort, 10 patients (23.3%) underwent T-TEER and 33 (76.7%) received medical therapy alone. T-TEER resulted in significant reduction in TR severity (p = 0.034), though 80% had residual moderate or greater TR. In conclusion, this commercial experience, rates of TTVR ineligibility were lower than previously described with large annular dimensions serving as the most frequent exclusion criterion. For those ineligible, T-TEER may provide a feasible approach in appropriately selected patients.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"264 ","pages":"Pages 1-6"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy Outcomes in Women with Cardiovascular Disease:A Retrospective Cohort Study from Kaiser Permanente Northern California","authors":"Ekta Partani MD ,&nbsp;Carol Shi MD ,&nbsp;Douglas Stram MS ,&nbsp;Samhita Palakodeti MD ,&nbsp;Marisa McDonald BSN, RN ,&nbsp;Cynthia Triplett MPH, MA ,&nbsp;Jennifer Ting MD ,&nbsp;Megan L. Stephenson MD ,&nbsp;Nikhil Joshi MD ,&nbsp;Seema K. Pursnani MD, MPH","doi":"10.1016/j.amjcard.2026.01.003","DOIUrl":"10.1016/j.amjcard.2026.01.003","url":null,"abstract":"<div><div>Cardiovascular disease (CVD) remains a leading cause of maternal mortality in the United States, comprising 26.5% of pregnancy-related deaths. We sought to evaluate trends in CVD during pregnancy and maternal, obstetric, and fetal outcomes in pregnant women with CVD in the Kaiser Permanente Northern California (KPNC) integrated healthcare system. This retrospective cohort study included adult KPNC members with moderate or greater valvular heart disease, cardiomyopathy, congenital heart disease, or ischemic heart disease during pregnancy from 2010 to 2021. Bivariate analyses and multivariable logistic regression were used to evaluate associations between demographic and clinical risk factors and maternal outcomes in pregnant patients with CVD. Of 320,902 pregnancies, 763 (0.24%) were identified with clinically significant CVD. The prevalence of CVD increased from 0.19% to 0.34% over the decade, predominantly due to an increase in prevalence of women with congenital heart disease. Mean gestational age at delivery was 36.7 weeks with 19.5% experiencing preterm delivery. Cesarean section, pre-eclampsia or eclampsia, and postpartum hemorrhage rates were 29.5%, 20.8%, and 9.7%, respectively. Fetal loss beyond the first trimester occurred in 7.1% pregnancies. Adverse maternal cardiac outcomes occurred in 55 (7.2%) of patients, predominantly driven by congestive heart failure hospitalizations. There were 4 deaths (0.5%) during pregnancy or within 1 year postpartum. Pre-existing CVD (aOR 0.20, p = 0.002) and cardiac medication use (aOR 4.13, p &lt;0.001) were significant predictors of adverse maternal outcomes. Higher left ventricular ejection fraction (aOR 0.95, p = 0.018) was associated with lower odds of adverse maternal outcomes. In conclusion, understanding risk factors for adverse pregnancy outcomes in a diverse, contemporary population of patients with CVD can help refine cardio-obstetric risk assessment and preconception counseling.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"264 ","pages":"Pages 7-13"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anomalous Attachment of the Posterior Mitral Annulus to the Crest of the Left Ventricle in Patients With Mitral Annular Disjunction (MAD) and Mitral Valve Prolapse","authors":"Jeffrey J. Silbiger MD ,&nbsp;Oksana Marchenko MD, PhD ,&nbsp;Raveen Bazaz MD ,&nbsp;Priya Panday MD ,&nbsp;Aviv Alter MD ,&nbsp;Pedro Rafael Vieira De Olivera Salerno MD","doi":"10.1016/j.amjcard.2025.11.026","DOIUrl":"10.1016/j.amjcard.2025.11.026","url":null,"abstract":"<div><div>The purpose of this study is to determine the site of attachment of the posterior mitral annulus to the left ventricle in patients with mitral annular disjunction (MAD) and mitral valve prolapse (MVP). The posterior annulus normally attaches to the inlet of the left ventricle. Some histological findings suggest that the disjunctive annulus may instead attach anomalously to the left ventricular (LV) crest in patients with MVP. We used cardiac magnetic resonance imaging to determine the site of attachment of the posterior mitral annulus (crest vs inlet) in 25 patients with MVP with MAD (MAD+ group) and 24 patients with MVP without MAD (MAD- group). The site of annular attachment was determined in the 3-chamber view during diastole. Our data demonstrate complete separation in mitral annular attachment site between MAD+ and MAD- groups. All patients in the MAD+ group demonstrated annular attachment to the LV crest, whereas all those in the MAD- group demonstrated annular attachment to the LV inlet (p &lt;0.001). The presence of anomalous annular attachment in MAD+, but not MAD- patients, suggests this anatomic abnormality represents a feature of the MAD phenotype rather than the myxomatous phenotype. Anomalous annular attachment may potentially influence the arrhythmic potential of MAD.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"263 ","pages":"Pages 27-32"},"PeriodicalIF":2.1,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective Use of Thromboaspiration in STEMI: CMR Evidence Against Routine Practice","authors":"Tom Bourcier MD ,&nbsp;Jeremie Riou MD ,&nbsp;Wissam Abi Khalil MD ,&nbsp;Thomas Benard MD ,&nbsp;Anicet Betard MD ,&nbsp;Audrey Camarzana MD ,&nbsp;Stéphane Delepine MD, PhD ,&nbsp;Serge Willoteaux MD, PhD ,&nbsp;Alain Furber MD, PhD ,&nbsp;Fabrice Prunier MD, PhD ,&nbsp;Loic Biere MD, PhD","doi":"10.1016/j.amjcard.2025.11.024","DOIUrl":"10.1016/j.amjcard.2025.11.024","url":null,"abstract":"<div><div>Thromboaspiration (TA) has been proposed as an adjunct to primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) to reduce thrombus burden. However, its effect on microvascular perfusion remains uncertain, and concerns have been raised about its potential to aggravate microvascular injury. This study aimed to evaluate the impact of TA on microvascular obstruction (MVO) using cardiac magnetic resonance imaging in a large cohort of STEMI patients. We prospectively enrolled 460 STEMI patients treated with primary PCI within 12 hours of symptom onset. TA was performed in 193 patients (42%). Cardiac magnetic resonance was performed at day 6 and 3 months to assess infarct size and MVO. A propensity score-based average treatment effect analysis was used to adjust for baseline differences. Subgroup analyses were conducted according to symptom-to-treatment time, thrombus burden (thrombolysis in myocardial infarction thrombus score), and sex. TA was independently associated with higher MVO incidence (odds ratios [OR] 1.52; 95% confidence intervals [CI]: 1.16 to 1.98; p = 0.0024) and greater MVO extent (standardized mean differences 0.42; 95% CI: 0.02 to 0.72; p = 0.041). The association was particularly significant in patients reperfused beyond 6 hours (OR 3.46; 95% CI: 1.92 to 6.23; p &lt; 0.0001) and those with nonocclusive thrombus (thrombolysis in myocardial infarction thrombus score “1 to 4”) (OR 2.23; 95% CI: 1.29 to 3.85; p = 0.004). Sex-stratified analysis showed increased MVO risk in men (OR 1.52; 95% CI: 1.14 to 2.05; p = 0.005) but not in women. TA during primary PCI was associated with increased occurrence and extent of MVO, particularly in patients with delayed reperfusion or nonocclusive thrombus. These findings reinforce current ESC guidelines against routine TA use and suggest that its application should be restricted to carefully selected patients.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"263 ","pages":"Pages 8-13"},"PeriodicalIF":2.1,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging to Rule Out Thrombus Before Ablation","authors":"Bharat Rawlley MB, BS,&nbsp;Kartik Gupta MD","doi":"10.1016/j.amjcard.2025.12.009","DOIUrl":"10.1016/j.amjcard.2025.12.009","url":null,"abstract":"","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"263 ","pages":"Page 7"},"PeriodicalIF":2.1,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiography-Derived Index of Microvascular Resistance in Patients With Anterior ST-Segment Elevation Myocardial Infarction After Successful Primary Percutaneous Coronary Intervention","authors":"Ciro Pollio Benvenuto MD ,&nbsp;Domenico Galante MD ,&nbsp;Frederik Zimmermann PhD ,&nbsp;Andrea Viceré MD ,&nbsp;Vincenzo Viccaro MD ,&nbsp;Chiara Giuliana MD ,&nbsp;Simona Todisco MD ,&nbsp;Michele Bellamoli MD ,&nbsp;Luca Bettari PhD ,&nbsp;Diego Maffeo MD ,&nbsp;Francesco Burzotta PhD ,&nbsp;Antonio Maria Leone PhD ,&nbsp;Andrea Buono MD","doi":"10.1016/j.amjcard.2025.11.023","DOIUrl":"10.1016/j.amjcard.2025.11.023","url":null,"abstract":"<div><div>Microvascular dysfunction following primary percutaneous coronary intervention (pPCI) is a well-established determinant of adverse outcomes in ST-segment elevation myocardial infarction (STEMI) patients. Although the invasive Index of Microcirculatory Resistance (IMR) has demonstrated prognostic value, its reliance on thermodilution limits its routine applicability. Angiography-derived functional indices, already validated in the epicardial domain, may offer a simplified, non-invasive alternative for microvascular assessment. To evaluate the prognostic performance of the angiography-derived Index of Microcirculatory Resistance (AngioIMR), we retrospectively analyzed 180 consecutive patients undergoing percutaneous coronary intervention (pPCI) for anterior STEMI at Fondazione Poliambulanza, Brescia, between January 1, 2016, and February 1, 2024. AngioIMR was computed using the formula: AngioIMR = MAP × QFR × TFC. The primary endpoint was a composite of all-cause death, target vessel myocardial infarction, or hospitalization for heart failure. The secondary endpoint additionally included hospitalization for angina. Over a 5-years follow-up, primary and secondary endpoints occurred in 16 (8.9%) and 23 (13%) patients, respectively. The optimal AngioIMR cut-off was 43 (AUC 0.800; 95% CI: 0.714–0.887; p &lt;0.001), with sensitivity 87.5%, specificity 63.4%, PPV 18.9%, and NPV 98.1%. The incidence of both the primary and secondary endpoints were significantly higher in patients with AngioIMR ≥ 43: 18.9% versus 1.9% (p &lt;0.001) and 28.4% versus 1.9% (p &lt;0.001), respectively. AngioIMR ≥ 43 was associated with increased risk of adverse outcomes (HR: 9.5; 95% CI: 2.2–42.0; p &lt;0.001), and remained an independent predictor at multivariable analysis. In conclusion, AngioIMR may be a promising tool to stratify prognosis in patients with STEMI.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"263 ","pages":"Pages 1-6"},"PeriodicalIF":2.1,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Atherectomy in Severely Calcified Lesions in Impella-Supported High-Risk Percutaneous Coronary Intervention","authors":"Batlah Falah MD, MPH ,&nbsp;Duzhi Zhao MS ,&nbsp;Julia B. Thompson MS ,&nbsp;Mir B. Basir DO ,&nbsp;Bjorn Redfors MD, PhD ,&nbsp;Michael J. Schonning MS, MBS ,&nbsp;William W. O’Neill MD ,&nbsp;Jason Wollmuth MD","doi":"10.1016/j.amjcard.2025.11.019","DOIUrl":"10.1016/j.amjcard.2025.11.019","url":null,"abstract":"<div><div>Severe coronary artery calcification (CAC) complicates high-risk percutaneous coronary intervention (HRPCI), particularly in patients with impaired left ventricular function. Atherectomy may facilitate lesion preparation, but its use in high-risk settings is limited. We therefore aimed to assess the impact of CAC severity and atherectomy on outcomes in Impella-supported HRPCI. In the PROTECT III study (NCT04136392), 1,015 of 1,237 patients had data on CAC severity and atherectomy. Patients were grouped as severe CAC without atherectomy (<em>n</em> = 298), severe CAC with atherectomy (<em>n</em> = 326), and no severe CAC (<em>n</em> = 400). The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE: all-cause death, myocardial infarction, stroke/TIA, or repeat revascularization) at 30- and 90-days. Secondary endpoints included 1-year mortality, PCI-related complications, and hemodynamic instability. Patients with severe CAC had higher baseline SYNTAX scores and more left main disease. Atherectomy was associated with slightly longer procedural times, but not increased periprocedural complications or hemodynamic instability. At 90 days, MACCE was highest in the untreated severe CAC group (16.1% vs 12.6% vs 9.2%; overall log-rank p = 0.048). One-year mortality was also highest in this group (23.7%; p = 0.02). However, CAC severity and atherectomy use were not independent predictors of outcomes. Sensitivity analysis excluding patients with atherectomy but no severe CAC showed higher mortality risk in untreated severe CAC cases (adjHR: 0.59; overall p = 0.026). In conclusion, Severe CAC is common in patients undergoing Impella-supported HRPCI and is associated with worse outcomes. Atherectomy was safe but its benefit remains uncertain. These findings highlight the prognostic relevance of CAC and the potential role of calcium modification in HRPCI.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"263 ","pages":"Pages 14-21"},"PeriodicalIF":2.1,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}